Role of a latent soluble TNF receptor type I (hsTNFR I) fusion protein in targeted treatment of endometriosis

National Medical Journal of China

Volumn 90, Issue 11, 2010, Pages 768-771

  Xiong, Zhou Fang ^a   Hu, Sha ^a   Wang, Ze Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Endometriosis; Receptors; Tumor necrosis factor; Type I

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COMPLEMENTARY DNA; DOUBLE STRANDED DNA; HUMAN SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; HYBRID PROTEIN; LATENCY ASSOCIATED PEPTIDE; MATRIX METALLOPROTEINASE; PLASMID DNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; ENDOMETRIOSIS; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; PERITONEAL FLUID; PROTEIN CLEAVAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ASCITES FLUID; CYTOLOGY; FEMALE; GENETICS; PLASMID;

ASCITIC FLUID; CELL LINE; ENDOMETRIOSIS; FEMALE; GENETIC VECTORS; HUMANS; PLASMIDS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 84871404122     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.11.012     Document Type: Article

References (11)

1. Adams G, Vessillier S, Dreja H, et al. Targeting cytokines to inflammation sites. Nat Biotechnol, 2003, 21: 1314-1320.
2. Nagase H, Fields G B. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers, 1996, 40: 399-416.
3. Peng K W, Morling F J, Cosset F L, et al. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther, 1997, 8: 729-738.
4. Wriggers W, Chakravarty S, Jennings P A. Control of protein functional dynamics by peptide linkers. Biopolymers, 2005, 80: 736-746.
5. Richter O N, Dorn C, Rosing B, et al. The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis. Arch Gynecol Obstet, 2005, 271: 143-147.
6. Falconer H, Mwenda J M, Chai D C, et al. Treatment with anti-TNF monoclonal antibody (c5 N) reduces the extent of induced endometriosis in the baboon. Hum Reprod, 2006, 21: 1856-1862.
7. Koninckxl PR, Craessaertsl M, Timmermanl D, et al. Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod, 2008, 23: 2017-2023.
8. Antonio M, Martelli F, Peano S, et al. Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol, 2000, 48: 81-98.
9. Nenan S, Boichot E, Laqente V, et al. Macrophage elastase (MMP-12): a pro-inflammatory mediator? Mem Inst Oswaldo Cruz, 2005, 100: 167-172.
10. Mizumoto H, Saito T, Ashihara K, et al. Expression of matrix metalloproteinases in ovarian endometriosis; immunohistochemical study and enzyme immunoassay. Life Sci, 2002, 71: 259-273.
11. Chau Y, Tan F E, Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjugate Chem, 2004, 15: 931-941.